ArticleBlood vessels, thrombosis & hemostasis2026
On a quest for fingerprints of crystalglobulinemia on platelets and endothelium.
Article in Blood vessels, thrombosis & hemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crystalglobulinemia is a rare plasma cell dyscrasia characterized by the crystallization of monoclonal proteins within the systemic vasculature and tissues, leading to occlusive vasculopathy, nephropathy, and tissue ischemia. We investigated platelet and endothelial activation status in a patient with crystalglobulinemia presenting with thrombotic events and acute kidney injury before and after anticlonal therapy. Platelet function assessment revealed the presence of procoagulant platelets, characterized by phosphatidylserine exposure and increased P-selectin expression in the absence of external stimuli. This phenotype was reversed by ex vivo calcium chelation. Furthermore, evidence supports FcγRIIA-mediated platelet activation by crystal complexes. Platelet proteomic analysis demonstrated upregulation of complement-related proteins, apolipoproteins, and proteins involved in platelet activation pathways. In addition, crystal proteomic analysis identified immunoglobulin heavy constant gamma-1 and albumin in a 1:2 ratio. Endothelial gene expression was evaluated using real-time polymerase chain reaction after coculturing the patient's serum, isolated platelets, and citrated platelet-poor plasma with a serum-starved EA.hy926 endothelial monolayer. The patient's serum increased endothelial gene expression of ICAM-1 and ADAMTS13, whereas VCAM-1 and E-selectin were significantly reduced compared with participants, a phenotype typically observed under high shear stress conditions. Platelet and endothelial dysfunction correlated with disease activity and demonstrated partial reversal after treatment, highlighting potential implications for disease monitoring and therapeutic targeting.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.